ALBUTEROL Drug Patent Profile

When do Albuterol patents expire, and what generic alternatives are available?

Albuterol is a drug marketed by Armstrong Pharms, Genpharm, Ivax Sub Teva Pharms, Pliva, Amneal Ireland Ltd, Cipla, Lupin, Padagis Us, Sandoz, Actavis Mid Atlantic, Apotex Inc, Bausch, Copley Pharm, Epic Pharma Llc, Landela Pharm, Lexenpharm, Luoxin Aurovitas, Nephron, Pharmobedient, Ritedose Corp, Roxane, Sentiss, Sun Pharm, Teva Pharms, Watson Labs, Watson Labs Inc, Wockhardt Eu Operatn, Amneal Pharms, Chartwell Molecular, Chartwell Rx, Cosette, Hikma, Mova, Quagen, Teva, Rising, Acertis Pharms, Aizant, Am Therap, Amneal Pharms Co, Aurobindo Pharma Ltd, Dash Pharms Natco, Hibrow Hlthcare, Strides Pharma Intl, Sun Pharm Industries, Ucb Inc, Warner Chilcott, Zydus Pharms, Aiping Pharm Inc, and Watson Labs Teva. and is included in eighty-eight NDAs.

The generic ingredient in ALBUTEROL is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Albuterol

A generic version of ALBUTEROL was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31^st, 2007.

Summary for ALBUTEROL

US Patents:	0
Applicants:	50
NDAs:	88
Raw Ingredient (Bulk) Api Vendors:	133
Clinical Trials:	300
Drug Prices:	Drug price information for ALBUTEROL
Drug Sales Revenues:	Drug sales revenues for ALBUTEROL
DailyMed Link:	ALBUTEROL at DailyMed

See drug prices for ALBUTEROL

See drug sales revenues for ALBUTEROL

Recent Clinical Trials for ALBUTEROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	PHASE2
Indiana University	PHASE2
Massachusetts General Hospital	PHASE4

See all ALBUTEROL clinical trials

Medical Subject Heading (MeSH) Categories for ALBUTEROL

Adrenergic beta-2 Receptor Agonists

Bronchodilator Agents

Tocolytic Agents

US Patents and Regulatory Information for ALBUTEROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hibrow Hlthcare	ALBUTEROL SULFATE	albuterol sulfate	TABLET;ORAL	213524-001	Oct 8, 2020		DISCN	No	No
Luoxin Aurovitas	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE	albuterol sulfate; ipratropium bromide	SOLUTION;INHALATION	206532-001	Jul 8, 2020		DISCN	No	No
Watson Labs	ALBUTEROL SULFATE	albuterol sulfate	SOLUTION;INHALATION	077772-002	Sep 25, 2007		DISCN	No	No
Ritedose Corp	ALBUTEROL SULFATE	albuterol sulfate	SOLUTION;INHALATION	214531-001	Dec 28, 2021	AN	RX	No	Yes

Market Dynamics and Financial Trajectory of Albuterol

Last updated: February 19, 2026

What is the global market landscape for Albuterol?

Albuterol, marketed primarily as a bronchodilator, treats asthma and chronic obstructive pulmonary disease (COPD). The global inhaler drug market, valued at approximately $13.2 billion in 2022, is expected to grow at a compound annual growth rate (CAGR) of 4% through 2030, driven by rising respiratory disease prevalence.

Albuterol’s share within this market exceeds 30%, given its status as an over-the-counter (OTC) and prescription medication in multiple regions. North America dominates, accounting for 45% of sales, followed by Europe with 25%. Emerging markets like China and India are witnessing rapid growth, with increased healthcare access and urban pollution exacerbating respiratory conditions.

What are the key drivers influencing market growth?

• Increasing respiratory disease prevalence: Over 300 million asthma cases worldwide (Global Initiative for Asthma, 2022).
• Expanded diagnostic capabilities: Improved detection enhances prescription rates.
• Uptake of inhaler devices: Greater use of metered-dose inhalers (MDIs) fits with patient preferences for portable, easy-to-use devices.
• Patent expirations and generic entry: Moderate impact; newer formulations like nebulizer solutions and dry powder inhalers (DPIs) provide diversified revenue streams.
• Pricing and reimbursement policies: Variability across regions impacts access and sales volume.

How does competition affect the market?

Albuterol faces competition mainly from:

• Other short-acting beta-agonists (SABAs): Levalbuterol, terbutaline.
• Combination inhalers: Formoterol/budesonide, salmeterol/fluticasone.
• Generic versions: Widely available since patent expirations in the early 2010s, reducing prices and market margins.

Major market players include GlaxoSmithKline, Teva Pharmaceutical Industries, and Sunovion Pharmaceuticals,holding significant shares via patented formulations and strategic distribution channels.

What are the recent regulatory and policy impacts?

• FDA and EMA approvals: Queries about inhaler device innovation, with regulations emphasizing drug-device combination products.
• Environmental concerns: The phase-out of chlorofluorocarbon (CFC) inhalers has increased adoption of hydrofluoroalkane (HFA) inhalers.
• Sustainability measures: Push for environmentally friendly inhalers influences product development, potentially impacting costs and timelines.

How does patent status influence future revenue?

Most original formulations patent expired around 2010-2012. Current sales predominantly derive from generics and newer device technologies. The expiration leads to price reductions but also stimulates market expansion through increased accessibility.

The development pipeline is limited; most innovation focuses on device delivery and combination therapies. Potential new formulations or delivery methods could offer additional revenue but are contingent on regulatory approval timelines and clinical trial success.

What is the forecasted financial trajectory?

Metric	2022	2025 (projected)	2030 (projected)
Global sales value	$4.2 billion	$5.6 billion	$7.8 billion
Market CAGR	N/A	4%	4%
Generic market share	75%	80%	85%
R&D expenditure	$50 million (approx.)	$60 million	$70 million

The growth assumes steady demand in established markets and expansion into emerging economies. Market expansion is limited by price pressures due to generic competition. R&D investments focus on inhaler device innovation and combination therapies to sustain margins.

What risks could impact future growth?

• Patent cliff effects reducing premium pricing.
• Regulatory delays for new device or formulation approvals.
• Environmental regulation shifts affecting inhaler design.
• Market saturation in mature regions.
• Price controls and reimbursement caps in healthcare systems.

Key Takeaways

• Global Albuterol market remained robust in 2022, with a valuation around $4.2 billion.
• The CAGR from 2022 to 2030 is projected at 4%, driven by demographics, device innovation, and expanding markets.
• Patent expirations have lowered prices but increased market accessibility via generics.
• Competition from other SABAs and new delivery systems shape the competitive landscape.
• Regulatory and environmental policies are primary factors influencing product development and market expansion.

FAQs

Q1: How does patent expiration affect Albuterol pricing?
Patent expiration introduces generic competition, leading to significant price reductions and a decline in branded sales margins.

Q2: What regions present the most growth opportunities?
Emerging markets such as China and India show increased respiratory disease burdens and improving healthcare infrastructure, offering growth potential.

Q3: Are there new formulations in development?
Most R&D focuses on improved inhaler devices and combination therapies rather than novel Albuterol molecules, due to patent expirations and market saturation.

Q4: How does environmental regulation impact Albuterol products?
Regulations phasing out CFC inhalers favor HFA inhalers, prompting industry shifts toward environmentally friendly delivery systems.

Q5: What future innovations could influence market share?
Development of smart inhalers with digital tracking and inhaler tracking apps could enhance adherence and provide new revenue streams.

---

References

1. Global Initiative for Asthma. (2022). Global Strategy for Asthma Management and Prevention. Retrieved from https://ginasthma.org
2. MarketWatch. (2023). Inhalers Market Size, Share & Trends Analysis Report.
3. U.S. Food and Drug Administration. (2022). Regulatory updates on inhaler device approvals and environmental considerations.
4. IMS Health. (2022). Pharmaceutical Market Reports.